Interpretation of Sequential Measurements of Cancer Antigen 125 (CA 125), Carcinoembryonic Antigen (CEA) and Tissue Polypeptide Antigen (TPA) Based on Analytical Imprecision and Biological Variation in the Monitoring of Ovarian Cancer

The main objective with cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) monitoring of ovarian cancer patients is to detect an early change of disease activity with high reliability. We hypothesized that a monitoring scheme for ovarian cancer patients...

Full description

Saved in:
Bibliographic Details
Published inClinical chemistry and laboratory medicine Vol. 39; no. 6; pp. 531 - 538
Main Authors Tuxen, Malgorzata K., Sölétormos, György, Petersen, Per Hyltoft, Dombernowsky, Per
Format Journal Article Conference Proceeding
LanguageEnglish
Published Berlin Walter de Gruyter 01.06.2001
New York, NY
Subjects
Online AccessGet full text
ISSN1434-6621
DOI10.1515/CCLM.2001.089

Cover

Abstract The main objective with cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) monitoring of ovarian cancer patients is to detect an early change of disease activity with high reliability. We hypothesized that a monitoring scheme for ovarian cancer patients with serological tumor markers should take into account the stochastic variation, i.e. the probability that observed increases and decreases may solely be due to analytical imprecision and normal intra-individual biological variation. The aim of this study was to provide a detailed characteristic of the within-subject mean steady state concentrations and the associated variability in healthy individuals with an age distribution representative for ovarian cancer patients. Thirty-one healthy women with a median age of 55 years comprised the study population. Sixteen blood samples were collected from each subject in four series, with four samples per series, over a period of approximately 1 year. We found that, i) natural logarithmic-transformed concentrations were more homogeneously distributed between individuals than the original concentrations, ii) the within-subject mean steady state levels, the standard deviations, and the coefficients of variation differed among subjects, and iii) the steady state variability differed among the markers. In conclusion, our data indicate that the assessment of sequential CA 125, CEA, and TPA concentrations is more complex than hitherto recognized. We suggest that it is necessary to adjust the assessment criteria to the type of marker, and that assessment may be facilitated if based on natural logarithmic transformed concentrations.
AbstractList The main objective with cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) monitoring of ovarian cancer patients is to detect an early change of disease activity with high reliability. We hypothesized that a monitoring scheme for ovarian cancer patients with serological tumor markers should take into account the stochastic variation, i.e. the probability that observed increases and decreases may solely be due to analytical imprecision and normal intra-individual biological variation. The aim of this study was to provide a detailed characteristic of the within-subject mean steady state concentrations and the associated variability in healthy individuals with an age distribution representative for ovarian cancer patients. Thirty-one healthy women with a median age of 55 years comprised the study population. Sixteen blood samples were collected from each subject in four series, with four samples per series, over a period of approximately 1 year. We found that, i) natural logarithmic-transformed concentrations were more homogeneously distributed between individuals than the original concentrations, ii) the within-subject mean steady state levels, the standard deviations, and the coefficients of variation differed among subjects, and iii) the steady state variability differed among the markers. In conclusion, our data indicate that the assessment of sequential CA 125, CEA, and TPA concentrations is more complex than hitherto recognized. We suggest that it is necessary to adjust the assessment criteria to the type of marker, and that assessment may be facilitated if based on natural logarithmic transformed concentrations.The main objective with cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) monitoring of ovarian cancer patients is to detect an early change of disease activity with high reliability. We hypothesized that a monitoring scheme for ovarian cancer patients with serological tumor markers should take into account the stochastic variation, i.e. the probability that observed increases and decreases may solely be due to analytical imprecision and normal intra-individual biological variation. The aim of this study was to provide a detailed characteristic of the within-subject mean steady state concentrations and the associated variability in healthy individuals with an age distribution representative for ovarian cancer patients. Thirty-one healthy women with a median age of 55 years comprised the study population. Sixteen blood samples were collected from each subject in four series, with four samples per series, over a period of approximately 1 year. We found that, i) natural logarithmic-transformed concentrations were more homogeneously distributed between individuals than the original concentrations, ii) the within-subject mean steady state levels, the standard deviations, and the coefficients of variation differed among subjects, and iii) the steady state variability differed among the markers. In conclusion, our data indicate that the assessment of sequential CA 125, CEA, and TPA concentrations is more complex than hitherto recognized. We suggest that it is necessary to adjust the assessment criteria to the type of marker, and that assessment may be facilitated if based on natural logarithmic transformed concentrations.
The main objective with cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) monitoring of ovarian cancer patients is to detect an early change of disease activity with high reliability. We hypothesized that a monitoring scheme for ovarian cancer patients with serological tumor markers should take into account the stochastic variation, i.e. the probability that observed increases and decreases may solely be due to analytical imprecision and normal intra-individual biological variation. The aim of this study was to provide a detailed characteristic of the within-subject mean steady state concentrations and the associated variability in healthy individuals with an age distribution representative for ovarian cancer patients. Thirty-one healthy women with a median age of 55 years comprised the study population. Sixteen blood samples were collected from each subject in four series, with four samples per series, over a period of approximately 1 year. We found that, i) natural logarithmic-transformed concentrations were more homogeneously distributed between individuals than the original concentrations, ii) the within-subject mean steady state levels, the standard deviations, and the coefficients of variation differed among subjects, and iii) the steady state variability differed among the markers. In conclusion, our data indicate that the assessment of sequential CA 125, CEA, and TPA concentrations is more complex than hitherto recognized. We suggest that it is necessary to adjust the assessment criteria to the type of marker, and that assessment may be facilitated if based on natural logarithmic transformed concentrations.
Author Petersen, Per Hyltoft
Dombernowsky, Per
Tuxen, Malgorzata K.
Sölétormos, György
Author_xml – sequence: 1
  givenname: Malgorzata K.
  surname: Tuxen
  fullname: Tuxen, Malgorzata K.
– sequence: 2
  givenname: György
  surname: Sölétormos
  fullname: Sölétormos, György
– sequence: 3
  givenname: Per Hyltoft
  surname: Petersen
  fullname: Petersen, Per Hyltoft
– sequence: 4
  givenname: Per
  surname: Dombernowsky
  fullname: Dombernowsky, Per
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14130280$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/11506467$$D View this record in MEDLINE/PubMed
BookMark eNp1kkuP0zAUhbMYxDxgyRZ5A5qRSLHjPJeZMAMVraaIwmI2lutcF0NiB9tF9C_zK3BomEpIrK6s89n3XN9zHp1ooyGKnhE8IxnJXjfNYjlLMCYzXFYn0RlJaRrneUJOo3PnvgYhy9LicXRKSIbzNC_Ool9z7cEOFjz3ymhkJPoI33egveIdWgJ3Owt9OLpRargWYFEd1C1oRJIMXTb1WK9eBdEKpQ30G7s3WokH7LK5qa8Q1y1aK-d2gFam2w8weNXCEVqvAnTNHbQo-Kg17_ZeiWBi3gd7QrnR3vjItTKd2f6RPnOrDr6VRv4LoGVo7I1Vejvavfsx6nqy_SR6JHnn4OlUL6JPtzfr5l28uHs7b-pFLGhW-BhyWeZpUUBJW1lKISinbSmTMuVVIaRsZQJphQssk4S0CaloQdoWqg0Ap6SU9CJ6eXh3sCb8pPOsV05A13ENZudYQXBVJSQP4PMJ3G16aNlgVc_tnv3dTgBeTAB3YVxpwxzKHbmUUJyUOHDxgRPWOGdBHhHMxmSwMRlsTAYLyQg8_YcX6rB_b7nq_ntr6qKch58PLbj9xoLXImMf1ilrVrf3b3D-nt3T36klzpI
CitedBy_id crossref_primary_10_1016_j_cca_2011_11_012
crossref_primary_10_1159_000438861
crossref_primary_10_1177_0004563214534636
crossref_primary_10_4155_fsoa_2017_0023
crossref_primary_10_1177_0004563214555163
crossref_primary_10_1515_cclm_2021_0283
crossref_primary_10_1515_CCLM_2004_073
crossref_primary_10_1515_cclm_2021_0725
crossref_primary_10_1080_00365510310000439
crossref_primary_10_1373_clinchem_2004_040659
crossref_primary_10_1007_s12094_012_0756_8
Cites_doi 10.1200/JCO.1996.14.5.1545
10.1016/0305-7372(95)90002-0
10.1093/clinchem/29.1.25
10.1093/clinchem/36.9.1625
10.1093/clinchem/40.9.1671
10.1159/000217761
10.1200/JCO.2000.18.8.1733
10.1006/gyno.1999.5414
10.1016/0021-9681(70)90055-X
10.1093/clinchem/36.2.265
10.1002/ijc.2910510112
10.1515/CCLM.2000.066
10.1177/000456329102800301
10.1093/annonc/6.suppl_2.S31
10.1016/0090-8258(92)90031-D
10.3109/10408368909106595
10.1016/S0065-2423(08)60208-5
10.1097/00000658-198509000-00006
10.1515/CCLM.1999.089
10.1093/clinchem/27.3.493
10.1016/0002-9378(84)90035-8
10.1136/bmj.298.6689.1659
10.1016/0009-9120(95)91342-Z
10.1093/clinchem/39.10.2077
10.1177/000456329102800313
ContentType Journal Article
Conference Proceeding
Copyright 2002 INIST-CNRS
Copyright_xml – notice: 2002 INIST-CNRS
DBID BSCLL
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1515/CCLM.2001.089
DatabaseName Istex
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
EndPage 538
ExternalDocumentID 11506467
14130280
10_1515_CCLM_2001_089
ark_67375_QT4_CPFZD06K_Z
Genre Journal Article
GrantInformation_xml – fundername: Balkan Clinical Laboratory Federation
GroupedDBID ---
-~0
.GJ
0R~
0~D
29B
36B
4.4
53G
5GY
5RE
9-L
AAAEU
AABBZ
AAFPC
AAGVJ
AAILP
AALGR
AAONY
AAOQK
AAOWA
AAPJK
AAQCX
AAWFC
AAXCG
ABAOT
ABAQN
ABFKT
ABFQV
ABIQR
ABJNI
ABLJU
ABMIY
ABPLS
ABRDF
ABRQL
ABUVI
ABVMU
ABWLS
ABXMZ
ABYBW
ACEFL
ACGFS
ACIWK
ACMKP
ACPMA
ACPRK
ACXLN
ACZBO
ADALX
ADDWE
ADEQT
ADGQD
ADGYE
ADOZN
ADUQZ
AEDGQ
AEGVQ
AEICA
AEJTT
AEKEB
AENEX
AEQDQ
AERZL
AEXIE
AFAUI
AFBAA
AFBQV
AFCXV
AFGDO
AFGNR
AFQUK
AFRAH
AFYRI
AGBEV
AGGNV
AHOVO
AHVWV
AHXUK
AI.
AIERV
AIKXB
AJATJ
AJHHK
AKXKS
ALMA_UNASSIGNED_HOLDINGS
ALUKF
ALYBR
AMAVY
ASPBG
ASYPN
AVWKF
AZFZN
AZMOX
BAKPI
BBCWN
BCIFA
BSCLL
BWHEM
CAG
CGQUA
COF
CS3
DA2
DBYYV
DU5
EJD
F5P
FSTRU
HZ~
IL9
IY9
KDIRW
N9A
O9-
OVD
P2P
PQQKQ
QD8
RDG
SA.
SLJYH
TEORI
UK5
VH1
WTRAM
~Z8
AARRE
AAYXX
ABDRH
ACDEB
ACRPL
ACUND
ACYCL
ADNMO
ADNPR
AECWL
AFBDD
AFSHE
AGQPQ
AIWOI
CITATION
DSRVY
LVMAB
.55
1CY
354
AAFNC
AAOTM
AASQH
ABUBZ
EBS
EMOBN
IQODW
OBC
OBS
OEB
OES
OHH
X7M
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c357t-e6f86477e83df8fcc3a3d8f284a97cffdf2e49070f221d219371dde9beea318f3
ISSN 1434-6621
IngestDate Sat Sep 27 22:11:45 EDT 2025
Wed Feb 19 01:24:59 EST 2025
Wed Apr 02 07:47:36 EDT 2025
Wed Oct 01 03:08:39 EDT 2025
Thu Apr 24 23:11:43 EDT 2025
Wed Oct 30 09:36:56 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords Human
Concentration factor
Variability
Tissue polypeptide specific antigen
Tumoral marker
Malignant tumor
Female genital diseases
Ovarian diseases
Carcinoembryonic antigen
Ovary
Surveillance
CA 125 antigen
Female
Language English
License CC BY 4.0
LinkModel OpenURL
MeetingName 8th Meeting of the Balkan Clinical Laboratory Federation, Sinaia, 20-23 September 2000
MergedId FETCHMERGED-LOGICAL-c357t-e6f86477e83df8fcc3a3d8f284a97cffdf2e49070f221d219371dde9beea318f3
Notes istex:BD810E5740E3A42E59F3923D75F171EA3D235FB8
cclm.2001.089.pdf
ark:/67375/QT4-CPFZD06K-Z
ArticleID:cclm.39.6.531
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 11506467
PQID 71099216
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_71099216
pubmed_primary_11506467
pascalfrancis_primary_14130280
crossref_primary_10_1515_CCLM_2001_089
crossref_citationtrail_10_1515_CCLM_2001_089
istex_primary_ark_67375_QT4_CPFZD06K_Z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2001-06-01
PublicationDateYYYYMMDD 2001-06-01
PublicationDate_xml – month: 06
  year: 2001
  text: 2001-06-01
  day: 01
PublicationDecade 2000
PublicationPlace Berlin
New York, NY
PublicationPlace_xml – name: Berlin
– name: New York, NY
– name: Germany
PublicationTitle Clinical chemistry and laboratory medicine
PublicationTitleAlternate Clinical Chemistry and Laboratory Medicine
PublicationYear 2001
Publisher Walter de Gruyter
Publisher_xml – name: Walter de Gruyter
References Fraser CG (p_13) 1990; 36
p_23
Gion M (p_31) 1995; 6
p_25
Bast RC, Jr. (p_7) 1984; 149
Krebs HB (p_12) 1986; 67
Fraser CG (p_28) 1991; 28
Lytken Larsen M (p_24) 1991; 28
Martin EW (p_29) 1985; 202
p_16
Sölétormos G (p_33) 1993; 39
Rustin GJ (p_1) 1996; 14
Harris KH (p_20) 1983; 29
p_4
p_34
p_3
Rustin GJ (p_2) 2000; 18
p_6
p_14
p_8
Gadducci A (p_9) 1990; 11
Westgard JO (p_17) 1981; 27
Harris EK (p_21) 1990; 36
Chan DW (p_5) 1999
Plebani M (p_32) 1996; 16
p_30
p_10
Fraser CG (p_15) 1994; 40
p_11
Gowans EMS (p_19) 1989; 13
Andersen M (p_22) 1996; 3
References_xml – volume: 14
  start-page: 1545
  year: 1996
  ident: p_1
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1996.14.5.1545
– ident: p_3
  doi: 10.1016/0305-7372(95)90002-0
– volume: 29
  start-page: 25
  year: 1983
  ident: p_20
  publication-title: Clin Chem
  doi: 10.1093/clinchem/29.1.25
– volume: 36
  start-page: 1625
  year: 1990
  ident: p_13
  publication-title: Clin Chem
  doi: 10.1093/clinchem/36.9.1625
– volume: 67
  start-page: 473
  year: 1986
  ident: p_12
  publication-title: Obstet Gynecol
– volume: 40
  start-page: 1671
  year: 1994
  ident: p_15
  publication-title: Clin Chem
  doi: 10.1093/clinchem/40.9.1671
– volume: 16
  start-page: 2249
  year: 1996
  ident: p_32
  publication-title: Anticancer Res
– ident: p_11
  doi: 10.1159/000217761
– volume: 13
  start-page: 327
  year: 1989
  ident: p_19
  publication-title: Biochim Clin
– volume: 18
  start-page: 1733
  year: 2000
  ident: p_2
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2000.18.8.1733
– ident: p_4
  doi: 10.1006/gyno.1999.5414
– ident: p_16
  doi: 10.1016/0021-9681(70)90055-X
– volume: 36
  start-page: 265
  year: 1990
  ident: p_21
  publication-title: Clin Chem
  doi: 10.1093/clinchem/36.2.265
– ident: p_10
  doi: 10.1002/ijc.2910510112
– ident: p_34
  doi: 10.1515/CCLM.2000.066
– volume: 28
  start-page: 207
  year: 1991
  ident: p_28
  publication-title: Ann Clin Biochem
  doi: 10.1177/000456329102800301
– volume: 6
  start-page: S31
  year: 1995
  ident: p_31
  publication-title: Ann Oncol
  doi: 10.1093/annonc/6.suppl_2.S31
– ident: p_8
  doi: 10.1016/0090-8258(92)90031-D
– ident: p_25
  doi: 10.3109/10408368909106595
– ident: p_6
  doi: 10.1016/S0065-2423(08)60208-5
– volume: 202
  start-page: 310
  year: 1985
  ident: p_29
  publication-title: Ann Surg
  doi: 10.1097/00000658-198509000-00006
– ident: p_23
  doi: 10.1515/CCLM.1999.089
– volume: 27
  start-page: 493
  year: 1981
  ident: p_17
  publication-title: Clin Chem
  doi: 10.1093/clinchem/27.3.493
– volume: 149
  start-page: 553
  year: 1984
  ident: p_7
  publication-title: Am J Obstet Gynecol
  doi: 10.1016/0002-9378(84)90035-8
– ident: p_14
  doi: 10.1136/bmj.298.6689.1659
– volume: 3
  start-page: 197
  year: 1996
  ident: p_22
  publication-title: Endocrinol Metab
– ident: p_30
  doi: 10.1016/0009-9120(95)91342-Z
– volume: 39
  start-page: 2077
  year: 1993
  ident: p_33
  publication-title: Clin Chem
  doi: 10.1093/clinchem/39.10.2077
– volume: 11
  start-page: 127
  year: 1990
  ident: p_9
  publication-title: Eur J Gynaecol Oncol
– volume: 28
  start-page: 272
  year: 1991
  ident: p_24
  publication-title: Ann Clin Biochem
  doi: 10.1177/000456329102800313
– start-page: 722
  year: 1999
  ident: p_5
  publication-title: Philadelphia: WB Saunders
SSID ssj0015547
Score 1.6779417
Snippet The main objective with cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) monitoring of ovarian cancer patients...
SourceID proquest
pubmed
pascalfrancis
crossref
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 531
SubjectTerms Adult
Aged
Analysis of Variance
Biological and medical sciences
Biometry
CA-125 Antigen - blood
Carcinoembryonic Antigen - blood
Female
Female genital diseases
Gynecology. Andrology. Obstetrics
Humans
Immunoassay - standards
Immunoassay - statistics & numerical data
Longitudinal Studies
Medical sciences
Middle Aged
Ovarian Neoplasms - diagnosis
Ovarian Neoplasms - immunology
Quality Control
Reference Values
Tissue Polypeptide Antigen - blood
Tumors
Title Interpretation of Sequential Measurements of Cancer Antigen 125 (CA 125), Carcinoembryonic Antigen (CEA) and Tissue Polypeptide Antigen (TPA) Based on Analytical Imprecision and Biological Variation in the Monitoring of Ovarian Cancer
URI https://api.istex.fr/ark:/67375/QT4-CPFZD06K-Z/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/11506467
https://www.proquest.com/docview/71099216
Volume 39
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAZK
  databaseName: De Gruyter Complete Journal Package
  issn: 1434-6621
  databaseCode: AGBEV
  dateStart: 19950101
  customDbUrl:
  isFulltext: true
  dateEnd: 99991231
  titleUrlDefault: https://www.degruyterbrill.com
  omitProxy: false
  ssIdentifier: ssj0015547
  providerName: Walter de Gruyter
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dU9NAEL_hY0Z9U0StH3gP6sCUKPlomjyWEGCE0goBgZfMJbk4jJAyIXUs_7L_hLt3l49iGUdfSsltL2n3t7d7d7-9JeSdbTCLGzHTjChyNIs5uuZy7mpd29IxtRhiFNzR7R_Yu8fW59PO6dz8sMFaGhfRx_h2Zl7J_2gVroFeMUv2HzRbdQoX4D3oF15Bw_D6p45nuhqvTGyMy8JtYjdAqRb3z6c3z4tZTEOIFyWjurgQuSTVqqGgecSIC2RaFnhwZxtCFbHz28N37w0XdRRjQaJsxK-ifCIq6pTCKOj3lJTgago9Y2kImP_CaJXwpmwwRNk2etakLWjS7HIiF9svrq5zVQ5IdCQPjxJNP2C6z5qczSsxTuWKzz0S7Zn6HtVKxfGpfyCTlS6_jfJbVrDGii_SB1x73w8Gh_2BIDfuTPDapp3XexC7Z_vBYDtoD32YEhzJ3ob1HbYG_U3_8GDw9WjvrNlULrE0qGByIBfEhTb8Ijv5eFKypqW_sExLs22Z5F06FHk6kzKcpnfoKIfH1X_OTB_WEcd9eN5-H5cv8IRZt3bWJUHhjg-vmJU6BiWGszFPFg0TRvMFstjb2fRPqp01CB9FwaHywdW5s3DTT1O3nIrTFnHI-Ym8YXYDik1lzZf7J2UiOAsek-U6bZUOKyt5QuZ4tkQeeqVlLJEHfWUMT8mvaRugo5TWNkCbNoBNEjtUQZUC8umq18O_a-v0LvorsVXAPrQDXKnEPW3gvpYC1K9RgXkKD1JjnjYwLzqpMU8rzNOLjALmaY15fF6FefXcy-R42w-8XU0VPtFis9MtNG6nDiaIc8dMUieNY5OZiZNCJMncbpymSWpwywVnnRqGnkDMYXZ1CFPciHMGPjo1n5GFbJTxF4RGXYvpG5YecaZbRmwzmL6A042jJIGh2HBaZL1UcxirqgBYnOYyxNUBQEWIqMBitXoIqGiRD5X4tTwO515BgZlKiuXfkUPa7YRfAiv0htvnWxv2XnjeIitToKq7VUhukbclykKAC-5nsoyPxjch0shdQ7db5LkEX_1ZPDcVQsCXf-v8FXlUG_xrslDkY_4GZhlFtKIM5zdGSCtP
linkProvider Walter de Gruyter
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=proceeding&rft.title=Clinical+chemistry+and+laboratory+medicine&rft.atitle=Interpretation+of+sequential+measurements+of+cancer+antigen+125+%28CA+125%29%2C+carcinoembryonic+antigen+%28CEA%29%2C+and+tissue+polypeptide+antigen+%28TPA%29+based+on+analytical+imprecision+and+biological+variation+in+the+monitoring+of+ovarian+cancer&rft.au=TUXEN%2C+Malgorzata+K&rft.au=S%C3%96LETORMOS%2C+Gy%C3%B6rgy&rft.au=HYLTOFT+PETERSEN%2C+Per&rft.au=DOMBERNOWSKY%2C+Per&rft.date=2001-06-01&rft.pub=Walter+de+Gruyter&rft.issn=1434-6621&rft.volume=39&rft.issue=6&rft.spage=531&rft.epage=538&rft_id=info:doi/10.1515%2FCCLM.2001.089&rft.externalDBID=n%2Fa&rft.externalDocID=14130280
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1434-6621&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1434-6621&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1434-6621&client=summon